[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fertility":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,43,73,101,132,157,189,219,244,271,315,340,365,388,422,460,505,532,563,595,615,644],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642874","exploring-and-validating-biomarkers-in-menstrual-blood-100642874",false,"NCT07638085","Exploring and Validating Biomarkers in Menstrual Blood","MB1","Inclusion Criteria:Are female and aged 18 years or over Experienced menarche but not menopause Are willing and able to provide a menstrual blood sample collected using a menstrual cup Are willing to provide a self-administered vaginal swab Are willing and able to undergo collection of a peripheral venous blood sample Are able to understand the study procedures and requirements Are able and willing to provide written informed consent Are willing for their samples and associated study data to be used for the research purposes described in the study documentation Participants may be recruited from participating fertility clinics.\n\n\\-\n\nExclusion Criteria:\n\n* Are male or 17 years or younger Not experienced menarche or experienced menopause Currently pregnant Have an active vaginal, pelvic or systemic infection that may affect safe participation or sample integrity\n\nHave a known allergy, sensitivity or intolerance to the menstrual cup material Have any medical, anatomical or physical condition that would make use of a menstrual cup unsafe or impractical Have any condition which, in the opinion of the investigator or delegated clinician, would make participation unsafe, inappropriate or unsuitable Are unable or unwilling to provide written informed consent",true,"FEMALE","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study aims to find out whether menstrual blood can provide similar useful biological information to a standard blood sample taken from a vein in the arm as well as uterine biopsies and vaginal swabs.\n\nMenstrual and reproductive health have historically been under-represented in research, and menstrual blood remains an under-studied biological sample despite its potential value for understanding women's health.\n\nWomen aged 18 years and over who are currently menstruating may be invited to take part. Participants will attend a study visit during their menstrual period, where they will provide a menstrual blood sample collected using a menstrual cup and a small blood sample from a vein in the arm.The samples will be sent to a research laboratory and analysed to compare the biological information they contain.\n\nSome samples may also be processed to extract DNA and isolate cells for research purposes.\n\nThe study is low risk and is not expected to provide a direct medical benefit to participants. However, it may help improve understanding of whether menstrual blood could be used more widely in future women's health and fertility research. Participants will not receive individual results, as the tests are for research purposes only and are not designed to provide clinical information about their health.",[25],"Fertility",[27,28,29],"non invasive","menstrual blood","infertility","NOT_YET_RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-10","ACTUAL",{"date":36,"type":21},"2026-07-01",{"date":38,"type":21},"2029-04-30",{"name":40,"class":41},"Genie Fertility Ltd","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100639141","outcomes-for-patients-who-preserved-their-fertility-as-part-of-cancer-treatment-at-the-center-for-the-study-and-preservation-of-eggs-and-sperm-mapreservferti-100639141","NCT07601451","Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm: MaPreservFerti","Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon Between 2010 and 2024: an Assessment of Male Parenthood. MaPreservFerti","MaPreservFerti","Inclusion Criteria:\n\n* were between the ages of 18 and 60 at the time of fertility preservation\n* Underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.\n* underwent fertility preservation in the context of cancer treatment\n* who have indicated their consent to participate in the study by completing the questionnaire\n\nExclusion Criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision\n* Persons receiving psychiatric care\n* Persons admitted to a health or social care facility for purposes other than research\n* Adults subject to a legal protection measure (guardianship, conservatorship)","MALE","60 Years",{"count":54,"type":21},950,"Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential.\n\nCancer treatments-surgery, radiation therapy, and chemotherapy-can significantly impair fertility. They may cause sexual dysfunction (anejaculation, anerection), androgen deficiency, or permanent impairment of spermatogenesis. Yet the desire for parenthood ranks among the top three life goals of patients newly diagnosed with cancer, and 50% of patients wish to have a child in the future. Preserving male fertility is therefore a crucial issue.\n\nBefore puberty, this can be done by taking a testicular tissue sample, although this is still considered experimental. After puberty, a sample taken from ejaculate allows for the storage of sperm straws.\n\nThus, when a couple wishes to conceive, following a potential reassessment of spermatogenesis if it is impaired, Assisted Reproductive Technology (ART) can be performed with or without the frozen sperm.\n\nAccording to the literature, the sperm is typically used within 10 years of fertility preservation. Little data has been collected regarding whether men with a history of cancer conceive naturally or not. It is therefore important to gather this information regarding fatherhood, particularly whether men with a history of cancer have used ART or not, and whether frozen sperm was used or not, based on the results of the follow-up semen analysis performed after treatment.\n\nPrimary objective To describe fertility-whether spontaneous or following assisted reproductive technology (ART)-with or without the use of preserved gametes, among patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.\n\nSecondary objective:\n\nTo assess the population of men who preserved their fertility prior to cancer treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon between 2010 and 2024, specifically:\n\n* The number and clinical and epidemiological characteristics of the patients.\n* Describe post-cancer fertility\n* Understand CECOS's care protocols to improve the patient care pathway.\n* Describe the psychological difficulties at the time of collection that prevented the procedure and thus the preservation of fertility.\n* Determine the fate of preserved straws that were not used\n\nMethodology:\n\n* Retrospective analysis of data from the CECOS in Lyon between 2010 and 2024.\n* Information collected from the database: patient age, indication, type of fertility preservation performed (testicular tissue or ejaculate)\n* Subsequently, a paper and electronic questionnaire was sent to these same patients to collect data on their fertility following fertility preservation.\n* Information collected via the questionnaires: marital status, place of residence, paternity prior to cancer, type of cancer, treatment received, achievement of pregnancy after cancer and method (spontaneous pregnancy, reuse of straws at the center, or ART at another center), donation of gametes to research, or destruction if unused.\n\nThe CECOS in Lyon is an integral part of the Department of Reproductive Medicine and Biology at the Hopsices Civils de Lyon.\n\nPopulation studied: This study focuses on patients with a history of cancer who underwent gonadotoxic treatment and preserved their fertility at the CECOS in Lyon between 2010 and 2024\n\nInclusion criteria:\n\nThis study will include patients who:\n\n* were between the ages of 18 and 60 at the time of fertility preservation\n* underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.\n* underwent fertility preservation in the context of cancer treatment\n* who have indicated their consent to participate in the study by completing the questionnaire\n\nExclusion criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision\n* Persons receiving psychiatric care\n* Persons admitted to a health or social care facility for purposes other than research\n* Adults subject to a legal protection measure (guardianship, conservatorship)\n\nProcedure:\n\nAn information sheet will be sent to patients regarding the analysis of their medical data collected during their care, along with a questionnaire (see attached questionnaire) for the collection of prospective data. The materials will be sent either by mail (with a stamped envelope for free return shipping as part of the study) or electronically via a dedicated and secure CECOS email address for email responses.\n\nNumber of subjects : 950 Study duration : 1 year\n\nStudy location : Center for the Study and Preservation of Eggs and Sperm (CECOS)",[25,57,58],"Male Cancer","Oncofertility",[60,58,61,62],"Male cancer treatment","Male fertility preservation","Sperm cryopreservation","2026-05-15",{"date":65,"type":34},"2026-05-22",{"date":67,"type":21},"2026-06",{"date":69,"type":21},"2027-06",{"name":71,"class":72},"Hospices Civils de Lyon","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100636228","fertility-impact-of-microplastics---advancing-countermeasures-and-tracking-100636228","NCT07562958","Fertility Impact of Microplastics - Advancing Countermeasures and Tracking","FERTIMPACT","Inclusion Criteria:\n\n* Men: 18-55 years and women: 18-45 years (premenopausal).\n* Residence: ≥ 2 years in the participating region.\n* Ability to give informed consent and complete questionnaires (diet, lifestyle, occupational exposure).\n* Willingness to provide required samples: semen, serum, stool for men and for women serum, stool, follicular fluid and endometrial sample.\n* Availability for study visits and compliance with pre-analytical rules: Abstinence 2-7 days before semen collection and timed sampling in women (e.g., follicular phase or per protocol).\n* For patient cohort: diagnosed reproductive disorder per site SOPs (e.g., male factor infertility, endometriosis, diminished ovarian reserve).\n* For control cohort: no known infertility diagnosis; trying to conceive or healthy volunteers.\n* Necessary for all participants will be possess the ability to understand the information contained in the \"informed consent\" document.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Acute febrile illness or active urogenital\u002Freproductive tract infection in the last 4 weeks.\n* Systemic therapies likely to confound biomarkers within prespecified windows: chemotherapy\u002Fradiotherapy (past 12 months), high-dose corticosteroids\u002Fimmunosuppressants (past 3 months), hormonal stimulation outside scheduled ART cycles per protocol.\n* Substance abuse (investigator judgment) impeding consent\u002Fcompliance.","ALL","55 Years",{"count":83,"type":21},1000,"FERTIMPACT is a prospective clinical study based on the hypothesis that exposure to micro- and nanoplastics (MNPs) is associated with impaired reproductive function. The study will quantify MNPs in human reproductive biospecimens (semen, follicular fluid, endometrial samples, stool and serum) and evaluate their association with clinically relevant fertility parameters, including semen, follicular fluid, and endometrial samples quality, and assisted reproductive technology (ART) outcomes. By integrating biomonitoring with standardized clinical assessment, the study aims to provide robust evidence on exposure-effect relationships in real-world populations undergoing infertility evaluation. This will contribute to improved understanding of environmental determinants of reproductive health and support future risk assessment strategies.",[86,87,25],"Infertility","Microplastics Exposure",[25,89,90,91],"microplastics","IVF","micronanoplastics","2026-04-28",{"date":94,"type":34},"2026-05-01",{"date":96,"type":21},"2027-09",{"date":98,"type":21},"2030-10",{"name":100,"class":72},"University of Kragujevac",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100534418","validation-of-donor-oocytes-semi-automated-vitrification-100534418","NCT06238570","Validation of Donor Oocytes Semi-automated Vitrification","Validation of Semi-automatic Oocyte Vitrification by the GAVI® Machine in Medically Assisted Reproduction With Oocyte Donation","GAVIDO","Inclusion Criteria:\n\n* Egg donor\n* Oocyte puncture for donation\n* Good quality ovarian reserve (Antral follicle count evaluated by ultrasound: CFA ≥ 7)\n* Negative serology status (HIV, hepatitis B and C, syphilis, CMV and HTLV)\n* Absence of symptoms or COVID contact\n* Absence of genetic contraindication to egg donation\n* Woman able to give informed consent to participate in research\n* Woman affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Decline to participate\n* Pregnant and lactating woman\n* Person under guardianship, curatorship, deprivation of liberty, protection of justice","38 Years",{"count":111,"type":21},50,"INTERVENTIONAL",[114],"NA","Oocyte vitrification is an effective method of freezing which has been authorized in France since 2011. The arrival of this technique has led to real improvements in the survival rate of oocytes after warming compared to that observed after slow freezing, a method previously applied. Oocytes reheated after vitrification show excellent results in terms of vitality and recovery of cellular functionality. Indeed, the fertilization rates observed after using warmed and fertilized oocytes in Assisted Reproduction Technology (ART) by intracytoplasmic sperm injection (ICSI) are similar to those obtained with fresh oocytes.\n\nHowever, the manual vitrification techniques used until now involve a learning curve and a potential variability of the completion time depending on the operator and the number of oocytes to be vitrified.\n\nOocyte vitrification is a key step to optimize the chances of pregnancy in ART after using these oocytes. However, manual vitrification requires a learning curve, is technician-dependent and requires significant technical time.\n\nA semi-automatic vitrification device (GAVI®, Merck), which recently appeared on the market, has demonstrated its effectiveness in terms of speed of production and reproducibility of vitrification of embryos obtained in ART. To our knowledge, no study has analyzed the effectiveness of semi-automatic vitrification (GAVI®, Merck) on survival and oocyte quality after warming. It would therefore be interesting to evaluate the effectiveness of this automaton on oocyte vitrification in the context of oocyte donation and to determine the impact of semi-automatic vitrification on oocytes compared to manual vitrification.\n\nThe main objective of this study is to demonstrate the non-inferiority of vitrification semi-automated device (Gavi) of oocytes with regard to the oocyte survival rate, compared to the manual technique used in ART.\n\nThe investigator will compare the effectiveness of semi-automated vitrification device with the manual technique, in terms of ART results by comparing the fertilization rates, the number and quality of embryos obtained as well as the implantation rates in oocyte recipient patients. This study will then allow clinical application of the most efficient protocol for oocyte vitrification in the context of oocyte donation. A cost\u002Feffectiveness study will be carried out.",[117,118,25,119],"Vitrification","Egg Donor","Assisted Reproductive Technology",[25,121,117,119],"Egg donor","RECRUITING","2026-04-27",{"date":125,"type":34},"2026-04-30",{"date":127,"type":34},"2024-01-23",{"date":129,"type":21},"2026-12",{"name":131,"class":72},"University Hospital, Clermont-Ferrand",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":112,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100633791","developing-resource-interventions-for-healthcare-professionals-and-patients-to-improve-knowledge-about-fertility-in-primary-ciliary-dyskinesia-100633791","NCT07531277","Developing Resource Interventions for Healthcare Professionals and Patients to Improve Knowledge About Fertility in Primary Ciliary Dyskinesia","REproductive Health in PRimary Ciliary Dyskinesia: Developing User-informed Clinical and Educational Resources (REPRoDUCE)","REPRoDUCE","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. 'Highly likely' or confirmed diagnosis of Primary Ciliary dyskinesia, or being a healthcare professional, or representative from a stakeholder group e.g. patient led charity\n3. Able to understand and willing to sign the informed participant consent prior to participation\n\nExclusion Criteria:\n\n1. Unwilling to participate in the study\n2. Not meeting inclusion criteria\n3. Unable to understand or unwilling to sign the informed participant consent prior to participation",{"count":141,"type":21},30,[114],"This project will involve working with people with PCD and medical professionals to develop resources that will help patients and the people providing their care to better understand fertility and pregnancy safety in people with this condition.",[145,25,146,147],"Primary Ciliary Dyskinesia (PCD)","Pregnancy","Health Information Exchange","2026-04-08",{"date":150,"type":34},"2026-04-15",{"date":152,"type":21},"2026-04-01",{"date":154,"type":21},"2029-03-31",{"name":156,"class":72},"University of Southampton",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":112,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":42},"100602096","ablative-technique-for-ovarian-preservation-in-endometrioma-100602096","NCT07119060","Ablative Technique For Ovarian Preservation In Endometrioma","Monocentric, Controlled, Randomized Trial: Comparison of Pregnancy Rates in Women With One or More Endometriomas, Treated by Cystectomy, Plasma Vaporization, or Sclerotherapy","ATOPE","Inclusion Criteria:\n\n* Patient aged between 18 and 43 years (inclusive)\n* Patient diagnosed with endometriosis (by histology or imaging) and symptomatic, requiring surgery (pelvic pain and\u002For infertility and\u002For risk to an organ)\n* Pelvic MRI or ultrasound performed within the last year showing at least one endometrioma larger than 20 mm in diameter\n* Patient with an intention to conceive (probable or certain) after surgery\n* Patient informed and having signed the consent form\n* Patient covered by a social security scheme\n\nExclusion Criteria:\n\n* Intraoperative finding that the cyst is not an endometrioma\n* Patient under guardianship, conservatorship, or incapable of giving consent\n* Patient without sufficient understanding of the French language\n* Patient under judicial protection measures\n* Patient who is pregnant or breastfeeding","43 Years",{"count":167,"type":21},332,[114],"The goal of this clinical trial is to compare pregnancy rates after different surgical treatments for endometriomas in adult women who have one or more ovarian cysts (endometriomas) larger than 2 cm requiring surgery. The main questions it aims to answer are:\n\nHow many women become pregnant within 24 months after surgery ? What are the birth rates and different types of pregnancies (natural, with fertility treatments, and those continuing beyond 12 weeks)? How often do the endometriomas come back after surgery? What surgery-related complications occur? How do pain levels change after treatment?\n\nResearchers will compare different surgical treatment groups to see if one approach results in better pregnancy outcomes and fewer complications.\n\nParticipants will:\n\nBe randomly assigned to different surgical treatment groups Undergo surgery for their endometriomas and endometriosis Attend follow-up visits at 3 months and 24 months after the procedure Have their pregnancy outcomes, pain levels, and potential complications monitored throughout the study period",[171,25],"Endometrioma",[173,174,175,176,177,178,179],"surgery","endometrioma","endometriosis","kystectomy","sclerotherapy","plasma vaporization","fertility","2026-03-17",{"date":182,"type":34},"2026-03-19",{"date":184,"type":34},"2025-09-18",{"date":186,"type":21},"2035-01",{"name":188,"class":72},"Clinique Tivoli Ducos",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":112,"phases":200,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100617500","phase-2-refining-fertility-sparing-treatment-in-endometrial-carcinoma-based-on-molecular-classification-100617500","NCT07319429","Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）","FEMUS","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 45 years;\n2. Strong willingness to preserve fertility\u002Futerus: Patients who have fertility requirements and insist on preserving fertility; or patients who have no fertility requirements but insist on preserving the uterus;\n3. Newly diagnosed endometrial cancer: Pathologically diagnosed as endometrial cancer via endometrial biopsy, diagnostic dilation and curettage, or hysteroscopic examination;\n4. Recurrent patients: Patients with endometrial lesions who received conservative treatment previously and developed recurrent endometrial cancer, with an interval of more than 6 months from the last standardized treatment, or deemed eligible for enrollment by the researcher after evaluation;\n5. Imaging examinations (including pelvic enhanced MRI, upper abdominal enhanced CT\u002FMRI, chest non-contrast CT, or PET\u002FCT-MR) performed within 2 weeks before enrollment treatment initiation to confirm that the lesions are confined to the uterus without extrauterine involvement; for patients allergic to iodine contrast agents, MRI can be used instead of CT;\n6. Clear molecular subtypes: POLE-mutant, NSMP (no specific molecular profile), or MSI-H (microsatellite instability-high);\n7. Provide informed consent and sign the informed consent form;\n8. Good compliance and follow-up conditions, willing and able to complete scheduled follow-up visits at our hospital;\n9. No significant abnormalities in major organ functions, with relevant test values meeting the following requirements:White blood cell count ≥ 3×10⁹\u002FL or absolute neutrophil count ≥ 1.5×10⁹\u002FL; Platelet count ≥ 100×10⁹\u002FL; AST and\u002For ALT \\\u003C 2× upper limit of normal (ULN); Serum creatinine \\\u003C 2× ULN;\n10. Karnofsky Performance Status (KPS) score ≥ 90; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n11. Concurrent use of thyroid medications, calcium tablets, vitamin D, bisphosphonates, metformin, aspirin, etc., is permitted;\n12. Multidisciplinary Team (MDT) discussion is required before treatment initiation.\n13. Additional Targeted Inclusion Criteria Based on Different Molecular Subtypes： 1) POLE-mutant endometrial cancer: Pathologically and radiologically evaluated as FIGO 2023 Stage IA endometrial cancer; 2). dMMR (deficient mismatch repair)\u002FMSI-H endometrial cancer: Pathologically and radiologically evaluated as FIGO 2023 Stage I-II endometrial cancer; Patients with Lynch syndrome may have other Lynch-related tumors in other systems; 3) NSMP endometrial cancer: Pathologically and radiologically evaluated as FIGO 2023 Stage IA1 endometrioid carcinoma; Pathological grade: G1\u002FG2; Lesions confined to the endometrial layer; Immunohistochemistry: ER-positive, L1CAM-negative (\\\u003C 10% positive cells).\n\nExclusion Criteria:\n\n1. Unclear molecular subtype or refusal to undergo molecular subtyping;\n2. p53-abnormal molecular subtype;\n3. ER-negative confirmed by pathological immunohistochemistry;\n4. L1CAM-positive confirmed by pathological immunohistochemistry (L1CAM ≥ 10% positive cells);\n5. Received any of the following treatments within 6 months before enrollment: high-dose potent progestins (megestrol acetate or medroxyprogesterone acetate) for consecutive ≥ 3 months; GnRHa ± letrozole for consecutive ≥ 3 months; immune checkpoint inhibitors for consecutive ≥ 3 months; levonorgestrel-releasing intrauterine system (Mirena) for consecutive ≥ 3 months; other treatments that may affect efficacy evaluation;\n6. Contraindications to therapeutic drugs (immune checkpoint inhibitors, progestins, GnRHa, letrozole);\n7. Complicated with severe medical diseases or severe liver dysfunction;\n8. History of major organ transplantation;\n9. History of severe mental illness or cerebral functional disorders;\n10. History of autoimmune diseases requiring immunosuppressant therapy;\n11. History of substance abuse or drug addiction;\n12. Request for hysterectomy or other treatments except conservative drug therapy;\n13. Inability to comply with the study protocol;\n14. POLE-mutant\u002FNSMP endometrial cancer: Complicated with other gynecological malignancies; For non-gynecological malignancies, enrollment is permitted if MDT evaluation confirms no impact on fertility-preserving treatment, and excluded if it affects fertility-preserving treatment or efficacy evaluation;\n15. dMMR\u002FMSI-H endometrial cancer (non-Lynch syndrome): Complicated with other malignancies, and MDT evaluation confirms impact on the selection of fertility-preserving treatment regimens or efficacy evaluation.\n\nExclusion Criteria for Immune Checkpoint Inhibitor Use:\n\n1. Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting other stimulatory or co-inhibitory T-cell receptors (e.g., CTLA-4, OX-40, CD137);\n2. Received or planned to receive live vaccines within 30 days before the first dose of study intervention. Note: Inactivated vaccines are permitted;\n3. Known intolerance to study interventions (or any excipients);\n4. Diagnosed with immunodeficiency or receiving chronic systemic steroid therapy (≥ 10 mg prednisone per day or equivalent dose) or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention;\n5. Severe hypersensitivity reaction (≥ Grade 3) to PD-1\u002FPD-L1 monoclonal antibodies and\u002For any of their excipients;\n6. Active autoimmune diseases requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment and is permitted;\n7. History of (non-infectious) pneumonitis requiring steroid treatment or current pneumonitis;\n8. Active infection requiring systemic treatment;\n9. Known history of HIV infection;\n10. Known history of hepatitis B (defined as HBsAg-positive) or active hepatitis C virus infection (defined as detectable HCV RNA \\[qualitative\\]); a. Chronic hepatitis B virus (HBV) carriers: HBV carriers with normal liver function and low HBV DNA load (e.g., below the lower limit of detection or at a low level) may be considered for PD-1 treatment after comprehensive evaluation. During PD-1 treatment, close monitoring is required, and appropriate antiviral prophylaxis should be administered if necessary to ensure treatment safety and efficacy; b. Patients with well-controlled hepatitis B: Patients with hepatitis B who have achieved good disease control through long-term standardized antiviral treatment, with mild liver inflammation and fibrosis, basically normal liver function, and no obvious complications such as cirrhosis or liver failure may receive PD-1 treatment;\n11. Any history or current evidence of diseases, treatments, or laboratory abnormalities that the researcher believes may confound study results, interfere with the patient's ability to complete the study, or make trial participation not in the patient's best interest;\n12. Known mental illness or substance abuse disorder that may interfere with the patient's ability to comply with study requirements;\n13. Other exclusion criteria: Previous allogeneic tissue\u002Fsolid organ transplantation; Failure to fully recover from surgery and\u002For any surgical complications;\n14. Currently breastfeeding.","45 Years",{"count":199,"type":21},260,[201,202],"PHASE2","PHASE3","Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment.\n\nThe concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolutionized the diagnosis and management of EC. EC subtypes with distinct molecular features demonstrate substantial differences in biological behaviors and responses to pharmacotherapeutic interventions. Nevertheless, the role of molecular subtyping in guiding FST decision-making-both in terms of its applicability and specific mechanisms-remains an unmet research need worldwide.\n\nNotably, the POLE-mutant and microsatellite instability-high (MSI-H) subtypes display the highest sensitivity to immune checkpoint inhibitors, underscoring the clinical value of exploring their utility in FST. The no specific molecular profile (NSMP) subtype is sensitive to progestogens but lacks reliable predictive biomarkers-accurate pre-treatment prediction would enable tailored treatment selection, shorten treatment duration, and enhance therapeutic outcomes. In contrast, the p53-abnormal (p53abn) subtype is associated with a poor prognosis, and FST is therefore not recommended for this subgroup.\n\nBuilding on the aforementioned background and our research team's preliminary clinical findings, this project focuses on the field of FST for EC. To address the current challenges-including narrow indications, limited treatment options, suboptimal efficacy, and the absence of precise personalized regimens-we aim to conduct the world's first prospective multicenter umbrella trial based on EC molecular subtyping. Optimal novel diagnostic and therapeutic protocols will be developed for each molecular subtype, with the goals of optimizing existing FST strategies, improving FST efficacy and reproductive outcomes, expanding eligible indications, and providing high-quality clinical evidence for molecular subtype-guided FST in EC, thereby advancing the overall effectiveness of FST for EC patients.",[205,25],"Endometrial Cancer",[207,208],"Fertility-sparing Treatment","Molecular Classification","2026-03-11",{"date":211,"type":34},"2026-03-13",{"date":213,"type":34},"2026-01-25",{"date":215,"type":21},"2029-12-31",{"name":217,"class":72},"Fudan University",2,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":42},"100626600","reproductive-prognosis-in-women-seeking-offspring-after-medical-or-surgical-therapy-for-endometriosis-100626600","NCT07437742","Reproductive Prognosis in Women Seeking Offspring After Medical or Surgical Therapy for Endometriosis","La Prognosi Riproduttiva Nelle Donne Che Ricercano Prole Dopo Terapia Medica o Chirurgica Per Endometriosi: Studio Multicentrico Italiano","SURGENDO","Inclusion Criteria:\n\n* age \\\u003C40 years at the time of offspring research\n* previous ultrasound or surgical diagnosis of endometriosis made in one of the endometriosis referral centres participating in the study\n* search for offspring after diagnosis\n* consent to the use of pseudonymised data for research purposes.\n\nExclusion Criteria:\n\n* women without endometriosis\n* age \\>=40 years at the time of the search for offspring\n* women who have undergone demolition surgery\n* women who do not wish to have offspring\n* women who have not given consent for their pseudonymised data to be used for research purposes\n* severe male infertility factor (testicular sperm retrieval)","40 Years",{"count":229,"type":21},650,"The study aims to compare the percentage of women with endometriosis who undergo PMA after medical vs surgical treatment and to describe conception patterns, pregnancy rates, and number of live vessels in women seeking offspring with endometriosis.",[232,25],"Endometriosis",[179,175,173,234],"PMA","2026-02-24",{"date":237,"type":34},"2026-02-27",{"date":239,"type":34},"2024-10-01",{"date":241,"type":21},"2026-12-31",{"name":243,"class":72},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":16,"sex":51,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":112,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":42},"100620707","phase-2-plan-a-occlusion-and-reversal-system-feasibility-study-100620707","NCT07361120","Plan A Occlusion and Reversal System Feasibility Study","Prospective, Multicenter, Single-arm, Open Label, Interventional Clinical Trial Investigating the Safety and Effectiveness of the Plan A Male Contraceptive System.","Inclusion Criteria:\n\n1. Male subject who is seeking and suitable to undergo a vasectomy as a long-term form of contraception\n2. Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)\u002FEthics Committee (EC) approved informed consent form (ICF) for this study prior to initiation of any screening or study specific procedures\n3. 25 to 65 years of age at the time of consent\n4. Body Mass Index (BMI) \\\u003C31 kg\u002Fm2\n5. Good health for undergoing a vasectomy as confirmed by medical history, physical examination and clinical laboratory tests of blood and urine at the time of screening\n6. Normal semen analysis defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (6th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart\n7. In the opinion of the Investigator, subject is suitable to undergo a vasectomy as a form of long-term contraception\n8. Agreement to use an effective method of contraception during the entire clinical trial until the planned vasectomy\n9. Lives in close proximity to the trial site to enable provision of fresh semen samples unless the subject agrees to provide semen samples at the trial site or laboratory\n\nExclusion Criteria:\n\n1. (On exam, has any of the following); one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study.\n2. Prior testicular surgery, testicular injury or prior vasectomy with vasovasostomy (vasectomy reversal)\n3. Recurrent pain with ejaculations\n4. Has known allergic reaction to sulfur-containing products or has had a prior severe allergic response to injectable or implantable devices\n5. Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection\n6. History of prostatitis or benign prostatic hypertrophy requiring treatment\n7. Has undergone prior chemotherapy\n8. Has known current coagulopathy or other bleeding disorders\n9. Currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)\n10. Subjects with cystic fibrosis\n11. Subjects with a history of inguinal hernia repair\n12. Vulnerable subjects (e.g., subjects with cognitive challenges, incarcerated, etc.)\n13. Currently participating in another study involving an investigational device or drug (or has participated in a study within the last 30 days prior to screening).\n14. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities\n15. In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study\n16. Has any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.","25 Years","65 Years",{"count":254,"type":21},40,[201],"Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens.",[25,258,259],"Fertility, Male","Healthy Male Adults",[261],"Vasectomy, Fertility, Reproductive Health, Male Contraception, Vas Occlusion, No Scalpel Vasectomy,","2026-01-14",{"date":264,"type":34},"2026-01-22",{"date":266,"type":21},"2026-01",{"date":268,"type":21},"2026-09",{"name":270,"class":41},"Next Life Sciences",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":17,"minAge":279,"maxAge":197,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":281,"conditions":282,"keywords":291,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":42},"100612012","smartphone-vs-manual-interpretation-of-biomarkers-for-ovulation-and-luteal-phase-detection-smom-study-100612012","NCT07248046","Smartphone vs Manual Interpretation of Biomarkers for Ovulation and Luteal Phase Detection (SMOM Study)","Comparing Cervical Mucus, PDG, LH, and Basal Body Temperature Combinations for Ovulation and Luteal Phase Identification Using the Premom Smartphone App Versus User-Read Test Results: A Prospective Observational Study","SMOM","Inclusion Criteria:\n\n* Female, aged 16 to 45\n* Natural menstrual cycles equal or less than 35 days\n* Off hormonal contraception for more than 3 months\n* Current user of the Premom App\n* Willing to track cervical mucus, LH, PDG, and BBT for 3 full cycles\n* Lives within 50 km of study site in the Ottawa region\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current hormonal therapy or contraception\n* Known anovulatory disorders, e.g., Polycystic Ovary Syndrome, hypothalamic amenorrhea.\n* Very irregular or absent cycles\n* Not using the Premom App\n* Unable or unwilling to complete tracking or provide consent","16 Years",{"count":141,"type":21},"This study will compare different combinations of fertility signs (cervical mucus (CM), luteinizing hormone \\[LH\\], pregnanediol glucuronide \\[PDG\\], and basal body temperature \\[BBT\\]) to determine which are most reliable for identifying ovulation and luteal phase length. Thirty existing Premom App users will track daily observations for three menstrual cycles. Participants will record mucus, perform urine tests, upload test strip photos to the Premom App, and measure BBT. Both participant readings and AI-assisted app readings will be analyzed. The main goal is to find which marker pairings give the most accurate picture of ovulation timing and luteal phase length. Secondary goals include understanding ease of use, the number of tests required, and whether the app improves accuracy.",[25,283,284,285,286,287,288,289,290],"Mobile Applications","Artifical Intelligence","Cervical Mucus","Body Temperature","Luteinizing Hormone (LH)","Ovulation","Menstrual Cycle","Progesterone",[288,292,289,25,285,293,294,290,295,296,297,283,298,299,300,301,302,303,304,305],"Luteal Phase","Luteinizing Hormone","Pregnanediol Glucuronide","Basal Body Temperature","Female Reproductive Physiology","Fertility Awareness-Based Methods","Smartphone App","Artificial Intelligence","Self-Testing","Home Diagnostic Tests","Observational Study","Prospective Studies","Digital Health","Women's Health","2026-01-10",{"date":308,"type":34},"2026-01-13",{"date":310,"type":21},"2026-01-15",{"date":312,"type":21},"2026-11-15",{"name":314,"class":72},"Bruyère Health Research Institute.",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":227,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":339},"100600067","melafert-impact-of-adjuvant-therapy-on-fertility-in-patients-with-resected-melanoma-at-high-risk-of-relapse-100600067","NCT07092670","MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.","MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n1. Stage II, III, IV completely resected melanoma\n2. Female sex\n3. Under 40 years of age\n4. Not previously treated with chemotherapy and\u002For radiotherapy\n5. Being able to give written informed consent.\n\nExclusion Criteria:\n\n1. Unresectable melanoma\n2. Predisposing conditions for infertility\n3. Early menopause or family history of early ovarian failure (idiopathic, \\\u003C 45 years)\n4. Previous bilateral ovariectomy or other ovarian surgery\n5. Personal history of autoimmune diseases, endocrine disorders (except for hypothyroidism)\n6. Personal history of severe mental disorders associated with infertility (e.g., nervous anorexia) and\u002For requiring treatments that could impair fertility\n7. Inability to give written informed consent.",{"count":323,"type":21},270,"Melanoma survivorship in reproductive-age women is increasing due to the advent of effective therapies in the curative setting. However, while the impact on fertility and ovarian function of chemotherapy agents is well known, there is still a lack of consistent data regarding novel the Mitogen-activated protein kinase (MAP) kinase pathway inhibitors and immune-checkpoint inhibitors (ICIs) used in melanoma.\n\nA recent study showed that a single course of anti-PD-1 (PD, Programmed cell death protein 1) or anti-CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) reduced both the number and quality of oocytes in mice through an immune-mediated mechanism. In particular, primordial follicle damage cannot be restored, leading to relevant clinical implications.\n\nThe study aims to help to determine the impact of MAP kinase pathway inhibitors and ICIs on reproductive outcomes, and whether clinicians should discuss (and in what terms) fertility preservation techniques in reproductive-age women receiving ICIs and MAP kinase pathway inhibitors in the adjuvant setting.",[326,25],"Melanoma",[328,179,329],"MELANOMA","skin cancer","2025-09-04",{"date":332,"type":34},"2025-09-05",{"date":334,"type":34},"2025-08-04",{"date":336,"type":21},"2032-08",{"name":338,"class":72},"Intergruppo Melanoma Italiano",10,{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":348,"maxAge":109,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":362,"locationsCount":364},"100599400","observational-study-to-evaluate-fertility-in-women-between-32-and-38-years-old-treated-with-the-ovosicare-fertility-100599400","NCT07083999","Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility","Prospective Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility Food Supplement Containing a Combination of MYO\u002FDCI in a 3.6:1 Ratio, Antioxidants, Vitamins and Minerals","FERTILOBS","Inclusion Criteria:\n\n1. \\- Women who agree to participate in the study by signing the informed consent.\n2. \\- Between 32 and 38 years old.\n3. \\- Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months.\n\nExclusion Criteria:\n\n1. \\- BMI \\> 30 kg\u002Fm2.\n2. \\- Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of:\n\n   * Azoospermia\n   * Progressive motility \\\u003C25%\n   * Normal morphology ≤2%\n3. \\- Pregnant or breastfeeding women.\n4. \\- Patients with type 1 diabetes or thyroid disease.\n5. \\- Patients with any assisted reproduction technique scheduled during the duration of the study.\n6. \\- Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month.\n7. \\- Patients with a known allergy to any of the components of Ovosicare® Fertility.\n8. \\- Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult.\n9. \\- Patients with suspected endometriosis.\n10. \\- Existence of fibroids affecting the endometrial cavity.\n11. \\- Patients with 2 or more previous abortions.\n12. \\- Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.","32 Years",{"count":350,"type":21},300,"The goal of this observational study is to evaluate whether supplementation with the Ovosicare® Fertility food supplement increases the possibility of becoming pregnant in women aged between 32 and 38 years who have been trying to become pregnant for at least 6 months before starting supplementation.",[25],[346,146,354,355],"Food supplement","Ovosicare Fertility","2025-07-17",{"date":358,"type":34},"2025-07-24",{"date":360,"type":34},"2025-02-13",{"date":129,"type":21},{"name":363,"class":41},"Procare Health Iberia S.L.",27,{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":112,"phases":376,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":42},"100527924","phase-4-intensity-of-ovarian-stimualtion-and-euploid-embryos-100527924","NCT06154083","INtensity of OVarian Stimualtion and Euploid Embryos","The Impact of Ovarian Stimulation Intensity on Embryo Euploidy in Advanced Age Women","INOVEE","Inclusion Criteria:\n\n* Infertile patients with indication for IVF\n* Undergoing preimplantation genetic screening cycles\n* AMH \\>= 1.5 ng\u002Fml and \\\u003C 3.5 ng\u002Fml (AMH result of up to one year will be valid)\n* BMI 18.5 - 30 Kg\u002Fm2\n\nExclusion Criteria:\n\n* Severe male factor requiring TESE (testicular sperm extraction)\n* AMH \\\u003C 1.5 ng\u002Fml or \\>= 3.5 ng\u002Fml\n* Administration of any other drug potentially interfering with the treatment\n* Contraindication for hormonal treatment\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).\n* Monogenic disease to be detected with PGT-M","42 Years",{"count":375,"type":21},110,[377],"PHASE4","This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.",[25],"2025-02-25",{"date":382,"type":34},"2025-02-27",{"date":384,"type":34},"2023-12-12",{"date":63,"type":21},{"name":387,"class":72},"Fundación Santiago Dexeus Font",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":112,"phases":399,"briefSummary":400,"conditions":401,"keywords":407,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":42},"100570320","physical-activity-fertility-and-spontaneous-abortion-in-danish-couples-trying-to-conceive-100570320","NCT06705712","Physical Activity, Fertility, and Spontaneous Abortion in Danish Couples Trying to Conceive","A Preconception Cohort Study of Physical Activity, Fertility, and Spontaneous Abortion - Including a Randomized Controlled Trial.","SF\u002FActivity","Inclusion Criteria:\n\n* Female\n* 18-49 years\n* In a relationship with a male partner\n* Trying to conceive\n\nExclusion Criteria:\n\n* Using birth control\n* Receiving fertility treatment\n* Have been trying to conceive for more than six months","49 Years",{"count":398,"type":21},530,[114],"Physical activity in both the preconception period and during pregnancy may enhance the probability of getting pregnant and reduce the risks of complications during pregnancy. Adults, including pregnant women without complications, are recommended to be physically active for at least 30 minutes per day to maintain physical and mental health. Nonetheless, many women reduce their level of exercise during early pregnancy.\n\nWith this project, we will test the effectiveness of receiving motivational counseling on physical activity (PA) among women trying to conceive and during the first trimester of the pregnancy if they conceive. We will further investigate whether PA is associated with fecundability, spontaneous abortion (SAB) and other birth outcomes, i.e., gestational diabetes, preeclampsia, and birth weight.",[25,402,403,404,405,406],"Fecundability","Time-to-Pregnancy","Spontaneous Abortion","Pregnancy Outcome","Pregnancy Complications",[408,409,410,25,411,412,402,413],"Exercise","Physical activity","Sedentary behaviour","Spontaneous abortion","Preconception care","Time to pregnancy","2025-01-24",{"date":416,"type":34},"2025-01-28",{"date":418,"type":34},"2025-01-01",{"date":241,"type":21},{"name":421,"class":72},"University of Aarhus",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":431,"conditions":432,"keywords":438,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":4},"100577662","the-weight-of-victory-exploring-short--and-long-term-health-outcomes-in-former-male--female-elite-athletes-from-weight-sensitive-sports-100577662","NCT06801210","The Weight of Victory: Exploring Short- and Long-term Health Outcomes in Former Male & Female Elite Athletes from Weight-sensitive Sports","The Weight of Victory: Exploring Short- and Long-term Health Outcomes in Former Male & Female Elite Atheltes from Weight-sensitive Sports","Inclusion Criteria:\n\n* Represented the national team at senior and\u002For junior level, (Non-organized sports) competed at national and\u002For international level. , \\>1 year since retirement , \\>18 years old,and a proficient level of Norwegian reading and writing skills\n\nExclusion Criteria:\n\n\\-",{"count":430,"type":21},1500,"The health of former elite athletes has been identified as a critical research gap where there is limited knowledge about both short- and long-term consequences after ending their careers. The transition phase from an active elite career to everyday life has been shown to be particularly problematic, yet this issue has been little studied among former Norwegian elite athletes. Furthermore, questions remain regarding the health of athletes from weight-sensitive sports, such as weight-class, aesthetic, and certain endurance sports. These athletes face specific challenges related to maintaining a certain physique and frequent changes in body weight during their active careers. This group has been shown to be vulnerable to a range of problematic health outcomes related to low energy availability, and little is known about the long-term effects of a career involving this.\n\nTherefore, the overall purpose of the project is to map the mental and physical health of former elite athletes. At the same time, there will be a particular focus on the differences between weight-sensitive and less weight-sensitive sports, different types of sports, gender, as well as previous dieting and eating behaviors.",[433,25,434,435,436,437],"Musculoskeletal Health","Mental Health","Quality of Life","Body Image","Disordered Eating",[439,440,441,442,443,444,445,446,447,25,448,449,450,451],"Elite athletes","Mental health","Somatic health","Disordered eating","Musculoskeletal health","Quality of life","Anxiety and depression","Behavioral","Reproductive health","Harassment","Body acceptance","Personality traits","Weight regulation","2025-01-23",{"date":454,"type":34},"2025-01-30",{"date":454,"type":21},{"date":457,"type":21},"2025-06-30",{"name":459,"class":72},"Norwegian School of Sport Sciences",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":80,"minAge":4,"maxAge":4,"enrollmentInfo":467,"targetDuration":469,"studyType":22,"phases":4,"briefSummary":470,"conditions":471,"keywords":482,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":42},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":468,"type":21},2000,"20 Years","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[472,473,474,475,476,25,477,478,479,480,481],"Stem Cell Transplant","Stem Cell Transplantation","Oncological Outcomes","Oncological Patients","Oncological Children","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[465,483,484,485,179,486,487,488,489,490,491,492,493,494,495,480],"Fertility protection","Endocrinological follow-up after oncological disease","children","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplant","stem cell transplantation","2025-01-13",{"date":498,"type":34},"2025-01-16",{"date":500,"type":34},"2024-12-09",{"date":502,"type":21},"2044-11",{"name":504,"class":72},"University of Ulm",{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":513,"enrollmentInfo":514,"targetDuration":516,"studyType":22,"phases":4,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":42},"100570651","study-on-fertility-parameters-in-women-with-germline-variants-in-brca1-and-brca2-100570651","NCT06710015","Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","B.Fert: Retrospective and Prospective Observational Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","BFert","BRCA1 and BRCA2 carriers\n\nInclusion Criteria:\n\n* age \\> 18 years\n* presence of a pathogenic variant in the BRCA genes\n* signed informed consent Exclusion Criteria\n* presence of a pathogenic variant in another gene (not BRCA)\n* significant psychiatric or clinical impairment affecting the ability to consent to the study\n\nControl cohort\n\nInclusion Criteria:\n\n\\- Relatives up to the third degree of the first cohort who tested negative on predictive testing for the familial pathogenic variant in the BRCA genes, matched for age where possible.\n\nExclusion Criteria:\n\n* absence of a pathogenic variant in another gene (non-BRCA) found in a family member\n* significant psychiatric or clinical impairment affecting the ability to consent to the study","100 Years",{"count":515,"type":21},128,"1 Day","Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased risk of developing breast and ovarian cancers. According to current guidelines from the National Comprehensive Cancer Network, the risk of developing breast cancer exceeds 60% for both genes, while the risk for ovarian cancer ranges from 39% to 58% for the BRCA1 and from 13% to 29% for the BRCA2. The detection of a pathogenic variant in the BRCA1 or BRCA2 genes necessitates both the establishment of appropriate primary and secondary surveillance measures for carriers and the discussion of the familial implications of such findings.\n\nThe molecular basis initially suggesting a possible association between germline variants in BRCA1 and BRCA2 genes and diminished ovarian reserve lies in the cellular impact of impaired or defective repair of DNA double-strand breaks (DSBs) on oocytes. Notably, BRCA1 and BRCA2 genes play a key role in the ATM-related mechanism for DSB repair through the homologous recombination (HR) pathway.\n\nAlthough preclinical evidence supports a potential correlation between defective DSB repair and normal follicle maturation processes, clinical studies on large cohorts of patients with pathogenic BRCA1 and BRCA2 variants yield inconsistent results. This discrepancy is likely attributable to the inherent challenges in recruiting a sufficiently homogeneous and statistically significant sample size.\n\nThe aim of the study is to evaluate reproductive capacity in women carrying pathogenic variants in the BRCA1\u002F2 genes by assessing the number of pregnancies during the period from January 1, 2018, to December 31, 2023. Secondary objectives include evaluating menopausal characteristics and pregnancy outcomes.",[519,25,520,521,522],"BRCA1 and\u002For BRCA2 Variant Carriers","Reproductive Age","Menopause","Pregnancy Outcomes","2024-11-26",{"date":525,"type":34},"2024-11-29",{"date":527,"type":21},"2024-12-01",{"date":529,"type":21},"2026-06-01",{"name":531,"class":72},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":540,"enrollmentInfo":541,"targetDuration":543,"studyType":22,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls","50 Years",{"count":542,"type":21},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[546,25,547,548,549,550,551,552],"Childhood Cancer Survivors","Ovarian Reserve","CED","Ovarian Reserve Markers","Cryopreservation","Alkylating Agents","Female","2024-10-30",{"date":555,"type":34},"2024-11-01",{"date":557,"type":34},"2024-10-09",{"date":559,"type":21},"2028-12-31",{"name":561,"class":72},"Centre Hospitalier Universitaire de Liege",3,{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":594},"100407263","ovarian-reserve-and-bariatric-surgery-100407263","NCT04583150","Ovarian Reserve and Bariatric Surgery","Evolution of Ovarian Reserve in Severely Obese Women After Bariatric Surgery","BARIAOVO","Inclusion Criteria:\n\nObese women with planned surgery (BS group)\n\n1. Obese women with an indication of bariatric surgery (BMI ≥ 35 kg\u002Fm² with an obesity related comorbidity or BMI ≥ 40 kg\u002Fm²)\n2. Age 18 to 37 years (inclusion possible until the day before the 37th birthday)\n3. No pregnancy project in the next 12 months\n4. Signed informed consent\n5. Affiliated to The French social security except patient on AME (state medical aid)\n\nObese women with no planned surgery (control group)\n\n1. Obese women with BMI ≥ 35 kg\u002Fm²\n2. Age 18 to 37 years (inclusion possible until the day before the 37th birthday)\n3. No pregnancy project in the next 12 months\n4. Signed informed consent\n5. Affiliated to the French social security except patient on AME (state medical aid)\n6. Matched for age and BMI category (35-39.9 kg\u002Fm², 40-49.9 kg\u002Fm² and ≥ 50 kg\u002Fm²) with an operated woman\n7. No bariatric surgery project in the next 12 months\n\nExclusion Criteria:\n\nFor both groups : Obese women with planned bariatric surgery (BS group) and obese women with no planned surgery (control group):\n\n1. Medical condition known to alter ovarian reserve (previous oophorectomy, ovarian surgery, chemotherapy, pelvis or hypothalamic radiotherapy, known premature ovarian insufficiency …)\n2. Contraceptive with antigonadotropic action during the month before inclusion\n3. Pregnant or lactating woman\n4. HIV infection\n5. Previous bariatric surgery\n6. Expected follow up less than 3 years\n7. Absolute contraindication for bariatric surgery (vital risk, anaesthetic contraindication, non stabilized psychiatric disorder, substance addiction)","37 Years",{"count":573,"type":21},238,"The expansion of the obesity epidemic is accompanied with an increase in bariatric procedures, in particular in women of reproductive age. Severe obesity has negative effects on fertility and on in vitro fertilization (IVF) outcomes, and the weight loss induced by the bariatric surgery (BS) is believed to reverse the deleterious impact of overweight and obesity on female fertility. However, research is limited to retrospective cohort studies, small case-series and case-control studies. Weight reduction has been shown to improve fecundity and hormonal state of a subgroup of obese patients with polycystic ovary syndrome (PCOS). In this population, recent studies have demonstrated an increase of naturally conceived pregnancies following bariatric surgery. However, these studies have evaluated only short-term evolution of ovarian function and not all studies demonstrated improvements in fertility outcomes after BS. Clearly, more studies are needed regarding the effect of BS on obesity-related infertility, and long-term outcome of ovarian function has to be assessed.\n\nMarkers of ovarian reserve, including Follicle Stimulating Hormone (FSH), antral follicle count (AFC), and anti-mullerian hormone (AMH), have been used to counsel patients regarding in their reproductive outcomes. Serum AMH concentrations remain remarkably stable throughout the menstrual cycle, which is a great advantage over other markers of fertility. Various studies have evaluated the association between AMH and body mass index (BMI) but reported contradictory results. Some of them have reported a significant inverse correlation between AMH and BMI, but others found no relationship between AMH and BMI. Scarce and small preliminary studies have been performed to evaluate AMH changes after surgical weight loss and showed a decrease in serum AMH.",[576,577,578,25],"Bariatric Surgery","Obesity","Reproductive Health",[577,580,581,582,25,583,584],"Bariatric surgery","Gastric bypass","Sleeve","Anti-mullerian hormone","Ovarian reserve","2024-02-14",{"date":587,"type":34},"2024-02-15",{"date":589,"type":34},"2020-12-03",{"date":591,"type":21},"2028-03",{"name":593,"class":72},"Assistance Publique - Hôpitaux de Paris",14,{"id":596,"slug":597,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":218},"100530660","creation-of-a-biobank-of-fertile-men-100530660","NCT06189677","Creation of a Biobank of Fertile Men","Creation of a Biobank of Biological Samples From Fertile Men","Inclusion Criteria:\n\n* Normospermic male individuals\n* Naturally fertile male individuals\n* Male individuals \\> 18 years\n\nExclusion Criteria:\n\n* Non-normospermic male individuals\n* Male individuals who are not naturally fertile\n* Male individuals \\\u003C 18 years",{"count":468,"type":21},"Collection and conservation of human biological material from fertile subjects, i.e. men with previous parenthood (normospermic men, natural fathers).",[25],[25],"2023-12-19",{"date":608,"type":34},"2024-01-03",{"date":610,"type":34},"2016-06-16",{"date":612,"type":21},"2026-06-15",{"name":614,"class":72},"IRCCS San Raffaele",{"id":616,"slug":617,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":622,"targetDuration":624,"studyType":22,"phases":4,"briefSummary":625,"conditions":626,"keywords":631,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":218},"100449036","impact-of-the-microbiome-on-time-to-pregnancy-and-pregnancy-outcomes-in-fertile-women-attempting-to-conceive-100449036","NCT05127252","Impact of the Microbiome on Time to Pregnancy and Pregnancy Outcomes in Fertile Women Attempting to Conceive","SweBioFertil","Inclusion Criteria:\n\n* Women with a previous live birth in the past 5 years and planning a new pregnancy with the same male partner.\n* 18-40 years of age\n* Swedish personal identity number and a Swedish address (to send a sampling self-kit)\n* Sufficient understanding of spoken and written Swedish or English to provide informed consent and complete the web-based questionnaire.\n\nExclusion Criteria:\n\n* Women who do not have a child yet and plan to cease their contraception.",{"count":623,"type":21},500,"2 Years","This study aims to investigate the microbiome of women with previously proven fertility who plan to become pregnant.",[406,627,628,25,629,630],"Contraception","Pregnancy Loss","Microbial Colonization","Metabolome",[632,179,633,634],"cohort","microbiome","microbiota","2023-05-26",{"date":637,"type":34},"2023-05-30",{"date":639,"type":34},"2023-04-10",{"date":641,"type":21},"2026-12-30",{"name":643,"class":72},"Karolinska Institutet",{"id":645,"slug":646,"hasResults":11,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":11,"sex":17,"minAge":651,"maxAge":227,"enrollmentInfo":652,"targetDuration":653,"studyType":22,"phases":4,"briefSummary":654,"conditions":655,"keywords":657,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":218},"100276448","fertility-preservation-in-young-women-with-cancer-100276448","NCT02878434","Fertility Preservation in Young Women With Cancer","Fertility Preservation in Young Women With Cancer: an International Registration Study From the International Network on Cancer, Infertility and Pregnancy (INCIP)","Inclusion Criteria:\n\n* Young women who want to preserve their fertility during cancer treatment. Patients need to give their signed and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent","0 Years",{"count":468,"type":21},"5 Years","The researchers aim to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded.\n\nStudy population: All patients with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment.",[656,25],"Cancer",[656,25,146,658,659,660,661],"Chemotherapy","Radiotherapy","Long term","Follow up","2020-11-17",{"date":664,"type":34},"2020-11-18",{"date":666,"type":34},"2017-05-23",{"date":668,"type":21},"2032-07",{"name":670,"class":72},"University Hospital, Gasthuisberg"]